Optimistic Outlook on Tenax Therapeutics: Buy Rating Backed by Promising Clinical Developments
I'm PortAI, I can summarize articles.
William Blair analyst Matt Phipps maintains a Buy rating on Tenax Therapeutics (TENX) due to promising clinical trial developments, particularly the Phase III LEVEL trial for oral levosimendan. The trial shows high statistical power and lower variability, boosting confidence. Results are expected in the second half of 2026. Guggenheim also reiterated a Buy rating with a $25 target, highlighting the stock's potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments